Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.44 USD | +1.19% | +3.61% | +32.45% |
19/04 | Lake Street Starts Cellebrite DI With Buy Rating, $13 Price Target | MT |
01/04 | BofA Securities Adjusts Cellebrite DI Price Target to $13 From $12, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.45% | 2.32B | |
+11.45% | 3,096B | |
+10.53% | 85.37B | |
+5.81% | 77.1B | |
-13.42% | 54.31B | |
-22.40% | 47.92B | |
+24.99% | 47.74B | |
+19.52% | 42.15B | |
+66.74% | 38.06B | |
-9.41% | 24.73B |
- Stock Market
- Equities
- CLBT Stock
- News Cellebrite DI Ltd.
- BofA Securities Upgrades Cellebrite to Buy From Neutral on Solid Q4 Earnings, Business Momentum, Raises PT to $12 From $9